Abstract-Deterministic models describing mechanisms underlying tumor growth, suppression, and regrowth are proposed and fit to kinetic data on B cell lymphoma in mice. It is demonstrated that either a modest change in the effectiveness of killer cell suppression, or the existence of a variant nonimmunogenic clone of the tumor cells, can explain the regrowth of a tumor after initial suppression. Adjuvant immunotherapy after establishing the cancer dormancy is modeled as a stimulated increase of the flow of killer cells into the tumor or a local increase of the rate of proliferation of these cells in a tumor. We modeled the immunotherapy consisting of impulse injections of immune lymphocytes in the vicinity of the tumor. Our numerical experiments show that this immunotherapy does not completely destroy the tumor, although thereafter the tumor may persist in a dormant cancer state or have its regrowth markedly delayed.
INTRODUCTION
Tumors that originate in the body via a variety of mechanisms usually grow slowly. Many months or years may be needed for the existence of such a tumor to manifest itself. This near-steadystate existence of a tumor is described by the term cancer donnancy [1, 2] . Cancer dormancy is a well-recognized clinical phenomenon in which malignant cells persist for a prolonged period of time with little or no increase in the tumor cell population. This state may occur naturally or following apparently-effective therapy.
There are at least two plausible independent pathways to the clinically "quiescent state" of a tumor. The first pathway corresponds to intrinsic properties of the tumor cells (related to the expression of suppressor genes, production of growth, and/or antigrowth factors and corresponding receptors, etc.). The second pathway corresponds to approachin, m an equilibrium of interaction between the growing tumor cell population and various cellular and molecular components of the 08957177/01/S! -see front matter @ 2001 Elsevier Science Ltd. All rights reserved.
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immune system. In either or both situations, the tumor appears to be dormant. Nevertheless, tumor dormancy is not necessarily a stable state. Many factors-concomitant infection, stress, immunodepression events, changes in endocrine status, etc.-may disturb the balance between the host and the dormant tumor.
We will present a mathematical model for tumor growth and suppression below and show that this model can describe the regrowth of a dormant tumor by either of two distinct mechanisms.
The first mechanism is a modest decrease in the efficiency of immune-suppression of the tumor which, prior to this decrease, has been able to maintain an equilibrium state wherein the tumor does not exhibit growth. Variants of this mechanism have been studied in [3, 4] . The second mechanism we explore is the existence of a mutant clone of tumor cells which is not effectively suppressed by an immune response, and hence , grows unchecked, except for natural constraints imposed by nutrient resources.
In our model, tumor growth is reversed and then held in check by the continual attack of killer cells; however, when the equilibrium relationship between the killer cell and the tumor cell populations is suitably perturbed, the tumor "escapes" control and grows.
SINGLE CLONE MODEL FOR TUMOR REGROWTH
Let c(t) denote the number of cancer cells present at time t, measured in units of one million cells. Let e(t) denote the number of cytotoxic killer cells present at time t, measured in units of one million cells. Then the growth-rate of the cancer cell population is defined by the differential equation c'(t) = kc(t) (1 -be(t)) -ape(t)c(t).
The term Icc(1 -be) is the intrinsic rate of tumor cell growth. The parameter k is the maximal rate of tumor-cell growth (when b = 0, the tumor grows at the rate k,) and the parameter b is t,lie reciprocal of the maximal tumor cell population size; i.e., l/b = (the maximum number of tumor cells permitted to arise)/lO". The term apec specifies the rate of destruction of tumor cells. We cassume that killer cells bind with tumor cells, and that when this occurs then either (1) the tumor cell is destroyed, or (2) the killer cell is destroyed or inactivated.
(The event that both cells are destroyed is deemed negligible.)
The parameter p is the proportion of tumor cells bound with killer cells that will be destroyed. and 1 -p is the proportion of tumor-cell-killer-cell bound pairs where the killer cell is destroyed. The parameter a is defined so that a(1 -p) is the rate of killer cell destruction (after binding with a tumor cell), and ap is the rate of tumor cell destruction (after binding with a killer-cell). Note that 1 -a is the rate of neither cell killing the other after binding, and unbinding to try again. Thus, ay is the "kinetic" constant that multiplies e and c to form the overall tumor-cell destruction rate term ayec.
The growth-rate of the killer-cell population (which changes size as new killer cells are attracted and arrive via the lymph system) is defined by the differential equation e'(t)=?-+ ((f$;)) e(t) -de(t) -(a(1 -p)c(t)) e(t).
The parameter r is the base rate of arrival of killer cells at the tumor via the lymph system: we take r to be a derived parameter defined a.s eed, where ec = 0.3 (0.3 million is our estimate of t,he number of killer cells present in the absence of tumor cells taken from [3, 4] ). We have used the experimental data due to [5] , where BCLl lymphoma tumor cells were injected into the spleens of chimeric mice, and the resulting tumor growth was followed.
In dat,a from this group will be used to help estimate the parameters that define tumor growth by fitt,ing the pure growth model c'(t) = kc(t)(l -be(t)) with c(0) = 0.5.
It is appropriate to both fit and view the data and our fitted models in logarithmic form;
doing this is equivalent to weighting the data to assume the error in the tumor-size observations is more nearly log-normal than normal. The main purpose, however, is to introduce convenient units for both fitting and viewing.
In order to fit the data, we replicated our model for each of the Group 1, 2, and 3 data-sets, and introduced the pure-growth differential equation model mentioned just above for the Group 0 data. We have assumed that the initial number of killer cells contained in the spleen of the chimeric mice of Groups 1, 2, and 3 is 0.3 million, so we used t,he initial conditions e(0) = e0 for each replicated differential equation, where eo = 0.3. This indicates that eol0" is the number of killer cells that were initially present when the tumor cells were injected.
IVe used the MLAB mathematical and statistical modeling system from Civilized Software Inc., Bethesda, RIID, (see www. civilized.
corn [6] ) to fit our models and draw the corresponding graphs, since MLAB is especially designed to deal with differential equation models, including large systems of stiff equations.
For Figure 2 . This is clone by replacing p in our seven differential equations by the expression h(t), and defining /l(t) = if t < 150 then p else 0.9p. This result indicates that a modest decrease in immune response efiectiveness, corresponding to a small increase in the proportion 1 -p of killer lymphocytes being inactivated by tumor cells, dramatically changes the outcome of the disease.
It is worthwhile to note that suitably changing the parameters w, d, or k can produce a similar regrowth event. However, increasing the parameter g from 0.16 to 5 did not change approaching the trmior dormancy steady state. Thus, our modeling suggests that regrowth of a dormant tumor may be associated with diminishing immune system activity, caused by a variety of mechanisms. J/Iany immune functions are reduced with age [7] or chronic stress [8] . We explored the effect of diminishing the various immunological parameters in our model; we observed that slowly reducing the parameters p, v, d, or lo with age induced regrowth of the dormant tumor. Figure 3 shows that introducing a linear reduction of parameter 2, causes the tumor to leave the dormant state and regrow to a very large mass by 250 to 300 days after the initial challenge. The rate of tumor regrowth is about three times slower than the rate of primary tumor growth. This result agrees with the experimental data of Sui et al. [5] and Vitetta et al. [2] . The simulation of regrowth with diminishing immune activity shown in Figure 3 was done by linearly decreasing the parameter 7~
by replacing w with the expression ~(1 -p(t -q)), w lere Q = 150 days and p = 0.002 (l/day). 1
TWO CLONE MODEL FOR TUMOR REGROWTH
Another explanation of tumor regrowth is that there is a small population of immune 
'(t) = kc(t) (1 -b (c(t) + m(t))) -ape(t)c(t), m'(t) = 0.33/W(t) (1 -b (172(t) + C(t))) , e'(t) =r+ ((~~)~[~~)) e(t) -de(t) -(4 -p)c(t)) e(t),
with c(0) = CQ, m(0) = SCO, e(0) = eo, and f(t) = if t < u then 0 else v, where eo = 0.3 and CO is variously equal to 0.5, 5, and 50. We can estimate the value of s that causes the total tumor size c(t) + m(t) to rise to the value 500 after 290 days by simultaneously curve-fitting replicates of the function c(t) + ,m(t) to the point (290,500) for Groups 1, 2, and 3, along with the data for each group of chimeric mice. NJe also fit these model functions to the additional da.ta point (110, l), corresponding to 10" being the number of dormant tumor cells present initially at days 100 to 110 as estimated in [l] . MLAB permits such simultaneous fitting of many functions indirectly defined by differential equations. We obtained s = 4.081604 . 10m5 f 1.86. 10P5. The result is shown in Figure 4. 
SIMULATION OF IMMUNOTHERAPY FOR AN ESTABLISHED DORMANT CANCER
Inducing an increased presence of various cytokines, chemokines, and/or other immunomodulators in tumor tissue may augment the function of the immune system, and this can accomplished via. vaccine agents without serious toxicity, provided a rational approach is used [9] . Such t,herapeutic vaccine agents can indirectly enhance the influx of killer cells into tumor tissue. In Figure 5 , we show the results of numerically simulating the effects of changing the dynamics of the immune system via various vaccine regimes, thus modifyin g its action on an established dormant tumor. Such a change will result in reducing the tumor mass. However, this response is temporary, and tumor regrowth may occur after stopping the immunotherapy and thereby reducing the influx of killer cells. Figure 5a shows the result of increasing the flow of killer cells into a dormant tumor in three steps due to three imagined vaccine immunization treatments administered on day 180, day 194, and day 215. The modeled tumor is characterized by the parameters of a "normal" mouse obtained by fitting and exhibited in Figure 1 . In this case, we assume the vaccination provokes a temporary rise in the size of the population of killer cells available to attack the t,umor: this increase is independent of the (dormant) tumor-size. This is done by modifying the "base arrival rate" 0.3d by multiplying by factors that are temporarily greater than one, corresponding to each vaccine injection.
The therapeutic effect of vaccination shown in Figure 5a was modeled by the following equations. .
e'(t) = q(t)(0.3d) + e(t) -de(t) -a(1 -p)e(t)c(t), and c'(t) = kc(t) (1 -be(t)) -upe(t)c(t), with f(t) = if t < u then 0 else 21.
The effects of the vaccinations are described by the "multiplier" function cl, where
cl(t) = fl(t).fdt)h(t), and
fl(t) = 1 +.w(t,u1), Figure 5b shows the result of modeling such imagined immunizations beginning ten days after tumor regrowth has started in a mouse with a diminished immune response as modeled in Figure 2 ; thus, the vaccinations occur at days 160, 174, and 195. Also, in this case, we assullle our vaccine works by increasin, v the proliferation of killer cells in response to the logistic tumor size function. rather by increasin, m the arrival rate independently of the tumor size. This is done by multiplying the tumor-size dependent growth term for the killer cell population by factors which are temporarily greater than one, rather than modifying the base arrival rate as done above. Also. we assume that, alt,hough the number of killer cells increases in response to vaccination. t,heir effectiveness, as measured by the parameter p, remains diminished at a level 10% lower than t,he L~norn~al" mice modeled in Figure 1 . 
(t) -de(t) -a(1 -p)e(t)c(t), wiicl c'(t) = h(t)kc(t) (1 -k(t)) -ape(t)c(t), with
.f(t) = if t < '~1 then 0 else V, and h(t) = if t < 150 then p else 0.9~.
The effect,s of the vaccinations are here described by t,he "multiplier" function, cl. defined in terms of the functions fl, f2, f3, and UJ given above; fl, f2, f3, and w are defined as they were above, except that ~1 = 160, 212 = 174, and ug = 195. 1% used the initial conditions e(0) = 0.3, c(0) = 50, and the parameter values used for Figure 2 .
t,ogether with ~1 = 160, ~2 = 174, and ~3 = 195. Figure 5c shows the result of our simulation of the effect of immunotherapy by injecting immune memory cells in a mouse with a regrowing tumor due to a diminished immune response as modeled in Figure 2 (and Figure 5b) . We assumed that, soon after injection, the memory cells will increase the immune response to the tumor due to enhanced stimulation of the production of killer cells for a period of about 150 days. This mechanism of adaptive immunothera.py is modeled with the different,ial equations e'(t) = 0.3d + q(t) ((;y;;;)) e(t) -de(t) -a(1 -p)e(t)c(t), and c'(t) = h(t)kc(t) (1 -be(t)) -qe(t)c(t), with f(t) = if t < 11, then 0 else 'u: and /l(t) = if t < 150 then p else 0.9p.
The effects of the vaccinations are here again described by the "multiplier" funct,ion. q. defined in terms of the functions .fl, fi, fs, and 11); fl, fz, and f3 are defined as they were above, except t,hat, 11~1 = 160, 112 = 174, and 113 = 195. The function 'w has the same form as before, except that it. has been "lengthened" ( Figure 5d depicts the simulated situation where we modeled administering a "cyt,ostatic" drug t,hat has the effect of reducing the logistic growth-rate parameter k that governs the rate of t 1mior regrowth: this might be an agent that reduces the tumors' nutrient supply. for example.
In particular, we again used a reduced immune response mouse as described in Figure 2 which exhibits t,umor regrowt,h starting at clay 150. We imagine administering a drug that cuts the \-illur of li: in half on clay 170. This is done mat,hematically by replacing k: with the function X(t) = if t < 170 then k: else k/2.
DISCUSSION
Animal models of tumor dormancy are essential for understanding fundamental aspects of cancer biology and for exploring therapeutic strategies that may reduce the risk of tumor relapse [l] . Nevertheless, tumor dormancy has received surprisingly little scientific attention and experimental studies have been minimal. In this article, we have focused on the mathematical analysis of ~vell-est,Ablishecl data of BCLl lymphoma induced in chimeric mice [5] and explored its prognosis rintler various assumptions.
The assumption that, after the introduction of tumor cells (at time 0), no enhanced immune response occurred during the first 28 days after t,he mice were challenged with such injections was key to obtaining the excellent fits exhibited in Figure 1 . The probability of inactivation of an immune killer cell after binding to a tumor cell is also a crucial parameter of the model. The value of p, as well as the numerical values of the other kinetic parameters of our model, are t,ypical of the kinetic characteristics of CD8+ cytotoxic T lymphocytes involved in t,he allogenic immune response in mice. R.ecent.ly. two dist,inct experimental groups [9, 10] have reported that cytotoxic T lymphocytes are a major component in the regulation of tumor dormancy of BCLl lymphoma. This is furt,her confirmation that our killer cell population is primarily composed of CD8 'I' lymphocytes RS assumed in (3, 4] . It has been shown that immune T lymphocytes can recognize icliotype determinant,s of immunoglobulin molecules on the surface of B-cell lymphoma cells and can induce the local production of interferon-y (see [I] ). We have studied two related mechanisms of tumor regrowth. The first model predicted that a smH11 permanent reduction in the level of antitumor immune response may provoke the regrowth of a monoclonal tumor from a dormant state. Reducing the probability of killing or inactivation of a tumor cell by an immune killer lymphocyte, or reducing the rate of arrival of the immune lymphocytes into the tumor region, were the most critical factors in inducing t,he model t,o exhibit tumor regrowth. Various factors, i.e., aging, stress, infection, etc., may explain why such a. tumor-growth-inducing change might occur. Recently, Flood et al. [7] have observed a decline in a number of antigen-specific CD8+ cytotoxic T lymphocytes in mice with age and noted that t,his decline is associated with the susceptibility to an immunogenic tumor in such older animals, as our modeling corroborates.
Our second two-clone tumor model also agreed with the experimental observations. Under t,he assumption that a small fraction (0.004%) of the tumor cell population injected initially into the mice is nonimmunogenic and that the growth of this clone is three times slower than the immunological abnormality of a minor fraction of BCLl lymphoma cells was reported in the same study [2] .
Note t,hat the curves describing tumor regrowth presented above have distinct shapes. It would be interesting to see if tumor regrowth known to be due to immune system decline matches the regrowth profile in our first model while tumor regrowth due to the presence of a abnormal clone matches the regrowth profile of our second model.
Conducting a comparative immunological and genetic analysis of abnormal cell patterns in the original tumor and in tumor cells after dormancy would provide key information to validate 01 correct. our models. The abnormalities sought for could be defined by mutation or by epigenetic adaptation mechanisms.
Clinical and experimental observation confirms that intensive limited-term ilnlliunothelal,y does not provide complete tumor elimination, as predicted via modeling. Immunothelapy may reduce tumor mass to a handful of cells; however, if the functional activity of the immune system is slightly impaired, tumor regrowth after immunization is likely. Model-fitting predicts t,hat the life time of killer cells is short (about two days). Long term maintenance of anticancer immunity after stopping immunotherapy could be improved if long-life immune memory cells could be activated during immunization. Our modeling thus suggests that immune memory killer cells could be a critical target for immunization and vaccination strategies against BCLl lymphoma.
Moreover, memory cells could act to establish stable tumor dormancy and, perhaps in some cases, also eliminate dormant primary tumors and small metastatic tumors.
Finally, it would be useful to analyze the data of [5] with other models of cancer clormancy and its regrowth. such as models which follow a Gompetzian growth law [12, 13] . The development of I,hysical-chemical models which take into account the spatiotemporal distribution imd dynamics of tumor cells, immune cells, and cytokines as explored in [E-16] , could be helpful in bet,tel understanding cancer regrowth mechanisms and in optimizin, m therapeutic strategies to reduce the risk of tumor relapse.
